Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results

Kang, Sean, Verma, Subodh, Hassanabad, Ali Fatehi, Teng, Guoqi, Belke, Darrell D., Dundas, Jameson A., Guzzardi, David G., Svystonyuk, Daniyil A., Pattar, Simranjit S., Park, Daniel S.J., Turnbull, Jeannine D., Duff, Henry J., Tibbles, Lee Anne, Cunnington, Ryan H., Dyck, Jason R.B., Fedak, Paul W.M. · 2020 · Canadian Journal of Cardiology

Abstract

BACKGROUND Empagliflozin, an SGLT2 inhibitor, has shown remarkable reductions in cardiovascular mortality and heart failure admissions (EMPA-REG OUTCOME). However, the mechanism underlying the heart failure protective effects of empagliflozin remains largely unknown. Cardiac fibroblasts play an integral role in the progression of structural cardiac remodelling and heart failure, in part, by regulating extracellular matrix (ECM) homeostasis. The objective of this study was to determine if empagliflozin has a direct effect on human cardiac myofibroblast-mediated ECM remodelling. METHODS Cardiac fibroblasts were isolated via explant culture from human atrial tissue obtained at open heart surgery. Collagen gel contraction assay was used to assess myofibroblast activity. Cell morphology and cell-mediated ECM remodelling was examined with the use of confocal microscopy. Gene expression of profibrotic markers was assessed with the use of reverse-transcription quantitative polymerase chain reaction. RESULTS Empagliflozin significantly attenuated transforming growth factor β1-induced fibroblast activation via collagen gel contraction after 72-hour exposure, with escalating concentrations (0.5 μmol/L, 1 μmol/L, and 5 μmol/L) resulting in greater attenuation. Morphologic assessment showed that myofibroblasts exposed to empagliflozin were smaller in size with shorter and fewer number of extensions, indicative of a more quiescent phenotype. Moreover, empagliflozin significantly attenuated cell-mediated ECM remodelling as measured by collagen fibre alignment index. Gene expression profiling revealed significant suppression of critical profibrotic markers by empagliflozin, including COL1A1, ACTA2, CTGF, FN1, and MMP-2. CONCLUSIONS We provide novel data showing a direct effect of empagliflozin on human cardiac myofibroblast phenotype and function by attenuation of myofibroblast activity and cell-mediated collagen remodelling. These data provide critical insights into the profound effects of empagliflozin as noted in the EMPA-REG OUTCOME study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cjca.2019.08.033

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 37

  1. Fitchett, 2017, A practical guide to the use of glucose-lowering agents with cardiovascular benefit or proven safety, Can J Cardiol, 33, 940
  2. Mancini, 2017, Diabetes for cardiologists: practical issues in diagnosis and management, Can J Cardiol, 33, 366
  3. Verma, 2018, Empagliflozin increases cardiac energy production in diabetes novel translational insights into the heart failure benefits of SGLT2 inhibitors, JACC Basic Transl Sci, 3, 575, 10.1016/j.jacbts.2018.07.006 · DOI · Paper page
  4. Lopaschuk, 2016, Empagliflozin’s fuel hypothesis: not so soon, Cell Metab, 24, 200, 10.1016/j.cmet.2016.07.018 · DOI
  5. Sattar, 2016, SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?, Diabetologia, 59, 1333, 10.1007/s00125-016-3956-x · DOI · Paper page
  6. Kaul, 2016, Is the mortality benefit with empagliflozin in type 2 diabetes mellitus too good to be true?, Circulation, 134, 94, 10.1161/CIRCULATIONAHA.116.022537 · DOI
  7. Ngu, 2014, Human cardiac fibroblast extracellular matrix remodeling: Dual effects of tissue inhibitor of metalloproteinase-2, Cardiovasc Pathol, 23, 335, 10.1016/j.carpath.2014.06.003 · DOI
  8. Teng, 2015, Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis, Am J Physiol Heart Circ Physiol, 308, H1564, 10.1152/ajpheart.00126.2015 · DOI
  9. Lijnen, 2003, Transforming growth factor-β1–mediated collagen gel contraction by cardiac fibroblasts, J Renin Angiotensin Aldosterone Syst, 4, 113, 10.3317/jraas.2003.011 · doi:10.3317/jraas.2003.011
  10. Kobayashi, 2005, TGF-β1 and serum both stimulate contraction but differentially affect apoptosis in 3D collagen gels, Respir Res, 6, 141, 10.1186/1465-9921-6-141 · DOI
  11. Souders, 2009, Cardiac fibroblast: the renaissance cell, Circ Res, 105, 1164, 10.1161/CIRCRESAHA.109.209809 · DOI · Paper page
  12. Kanisicak, 2016, Genetic lineage tracing defines myofibroblast origin and function in the injured heart, Nat Commun, 7, 1, 10.1038/ncomms12260 · DOI · Paper page
  13. Edgley, 2012, Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β, Cardiovasc Ther, 30, 30, 10.1111/j.1755-5922.2010.00228.x · DOI
  14. Kong, 2014, The pathogenesis of cardiac fibrosis, Cell Mol Life Sci, 71, 549, 10.1007/s00018-013-1349-6 · DOI · Paper page
  15. Kusaka, 2016, Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome, Cardiovasc Diabetol, 15, 1, 10.1186/s12933-016-0473-7 · DOI
  16. Habibi, 2017, Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes, Cardiovasc Diabetol, 16, 9, 10.1186/s12933-016-0489-z · DOI · Paper page
  17. Verma, 2016, Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?, Diabetes Care, 39, 1, 10.2337/dc16-1312 · DOI · Paper page
  18. Shi, 2017, Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?, Mol Cell Biochem, 433, 97, 10.1007/s11010-017-3018-9 · DOI
  19. Rajasekeran, 2016, Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis, Kidney Int, 89, 524, 10.1016/j.kint.2015.12.038 · DOI
  20. Heerspink, 2016, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications, Circulation, 134, 752, 10.1161/CIRCULATIONAHA.116.021887 · DOI · Paper page
  21. Baartscheer, 2016, Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits, Diabetologia, 60, 568, 10.1007/s00125-016-4134-x · DOI · Paper page
  22. Ye, 2017, SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor, Cardiovasc Drugs Ther, 31, 119, 10.1007/s10557-017-6725-2 · DOI · Paper page
  23. Ye, 2018, Dapagliflozin attenuates Na+/H+ exchanger-1 in cardiofibroblasts via AMPK activation, Cardiovasc Drugs Ther, 32, 553, 10.1007/s10557-018-6837-3 · DOI
  24. Maly, 2002, Critical role of protein kinase C α and calcium in growth factor induced activation of the Na+/H+ exchanger NHE1, FEBS Lett, 521, 205, 10.1016/S0014-5793(02)02867-3 · doi:10.1016/s0014-5793(02)02867-3
  25. Orlowski, 2004, Diversity of the mammalian sodium/proton exchanger SLC9 gene family, Pflugers Arch, 447, 549, 10.1007/s00424-003-1110-3 · DOI · Paper page
  26. Engelhardt, 2002, Inhibition of Na+/H+ exchange prevents hypertrophy, fibrosis, and heart failure in β1-adrenergic receptor transgenic mice, Circ Res, 90, 814, 10.1161/01.RES.0000014966.97486.C0 · DOI · Paper page
  27. Juneman, 2013, Development of a novel sodium-hydrogen exchanger inhibitor for heart failure, J Cardio Vasc Med, 1, 1
  28. Chen, 2016, Exercise attenuates intermittent hypoxia-induced cardiac fibrosis associated with sodium-hydrogen exchanger-1 in rats, Front Physiol, 7, 1, 10.3389/fphys.2016.00462 · DOI
  29. Castella, 2010, A new lock-step mechanism of matrix remodelling based on subcellular contractile events, J Cell Sci, 123, 1751, 10.1242/jcs.066795 · DOI
  30. Godbout, 2013, The mechanical environment modulates intracellular calcium oscillation activities of myofibroblasts, PLoS One, 8, e64560, 10.1371/journal.pone.0064560 · DOI
  31. Raizman, 2007, The participation of the Na+-Ca2+ exchanger in primary cardiac myofibroblast migration, contraction, and proliferation, J Cell Physiol, 213, 540, 10.1002/jcp.21134 · DOI
  32. Follonier, 2008, Myofibroblast communication is controlled by intercellular mechanical coupling, J Cell Sci, 121, 3305, 10.1242/jcs.024521 · DOI
  33. Zhou, 2017, Characterization and standardization of cultured cardiac fibroblasts for ex vivo models of heart fibrosis and heart ischemia, Tissue Eng Part C Methods, 23, 422, 10.1089/ten.tec.2017.0169 · DOI
  34. Santiago, 2010, Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts, Dev Dyn, 239, 1573, 10.1002/dvdy.22280 · DOI · Paper page
  35. Scheen, 2014, Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor, Clin Pharmacokinet, 53, 213, 10.1007/s40262-013-0126-x · DOI · Paper page
  36. Ndefo, 2015, Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes, P T, 40, 364
  37. Seman, 2013, Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects, Clin Pharmacol Drug Dev, 2, 152, 10.1002/cpdd.16 · DOI

Cited by

See all 166

Metadata

Authors
Kang, S., Verma, S., Hassanabad, A. F., Teng, G., Belke, D. D., Dundas, J. A., Guzzardi, D. G., Svystonyuk, D. A., Pattar, S. S., Park, D. S. J., Turnbull, J. D., Duff, H. J., Tibbles, L. A., Cunnington, R. H., Dyck, J. R. B., & Fedak, P. W. M.
Venue
Canadian Journal of Cardiology
Publisher
Elsevier BV
Published
2020-04
Volume
36
Issue
4
Pages
543-553
ISSN
0828-282X (ISSN-L)
OpenAlex
W2996517820
Cited by
166
References
7
FWCI
12.23
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Canadian Institutes of Health Research
  • Heart and Stroke Foundation of Canada
  • Alberta Innovates - Health Solutions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. https://app.cochat.ai/papers/10.1016/j.cjca.2019.08.033
The paper
Kang, S., Verma, S., Hassanabad, A. F., Teng, G., Belke, D. D., Dundas, J. A., Guzzardi, D. G., Svystonyuk, D. A., Pattar, S. S., Park, D. S. J., Turnbull, J. D., Duff, H. J., Tibbles, L. A., Cunnington, R. H., Dyck, J. R. B., & Fedak, P. W. M. (2020). Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2019.08.033

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.